This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Memantine for Ophthalmic Indications

Allergan plc

Drug Names(s): Memantine for Ophthalmic Indications

Description: Memantine acts as an NMDA glutamate receptor antagonist.

Deal Structure: Allergan has licensed certain rights to the technology underlying Memantine fromChildren's Medical Center Corporation and Merz + Co. GmbH & Co.

Actavis and Allergan
In November 2014, Actavis and Allergan announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14, 2014, the transaction is valued at approximately $66 billion, or $219 per Allergan share.

In March 2015, Actavis announced that it has completed the acquisition of Allergan in a cash and equity transaction valued at approximately $70.5 billion.

In June 2015, Actavis announced that the company has adopted Allergan as its new global name and will begin trading under a new symbol (AGN). The company name change follows the acquisition of Allergan in March 2015 and the approval of the name...See full deal structure in Biomedtracker

Partners: Merz Pharmaceuticals GmbH


Memantine for Ophthalmic Indications News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug